Evidence map›Paper›PMID 40235602›Full record

ReviewFocus (American Psychiatric Publishing)2025

Cognitive Deficits in Late-Life Depression: From Symptoms and Assessment to Therapeutics.

Antonio L Teixeira, Allison Gregg, Melanie T Gentry, Swathi Gujral, Ellie Rapp, Lauren Oberlin, Olusola Ajilore, Sara Weisenbach, Regan Patrick

Abstract readReview
In one paragraph

Review in Focus (American Psychiatric Publishing), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Antonio L TeixeiraBiggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore).ORCID https://orcid.org/0000-0002-9621-5422
Allison GreggBiggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore).
Melanie T GentryBiggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore).ORCID https://orcid.org/0000-0002-9484-3206
Swathi GujralBiggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore).
Ellie RappBiggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore).
Lauren OberlinBiggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore).
Olusola AjiloreBiggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore).ORCID https://orcid.org/0000-0003-0737-0437
Sara WeisenbachBiggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore).
Regan PatrickBiggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore).

Funding

Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital TherapeuticsK23MH129882 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI Lauren Elizabeth Oberlin · 2023 to 2026
$775k
NIMH NIH HHS K23 MH129882
6 · The paper itself

Abstract

Cognitive symptoms and deficits are core features of late-life depression (LLD), with an estimated 20%-50% of affected individuals meeting diagnostic criteria for mild cognitive impairment (MCI). Cognitive deficits, especially executive dysfunction, have consistently been associated with poorer treatment outcomes among people with LLD. Furthermore, distinguishing depression with cognitive complaints or cognitive impairment from the early stages of Alzheimer's disease (AD) can be challenging. Cognitive concerns are often emphasized among those with LLD, although, paradoxically, their description of memory difficulty may include detailed recall of specific memory lapses. Conversely, people with AD often have limited insight into their progressive cognitive decline, minimizing and concealing their cognitive difficulties. Neuropsychological assessment is one of the most useful means of clarifying this differential diagnosis. A subcortical cognitive pattern is commonly observed among people with LLD, including psychomotor slowing, variable attention, and executive dysfunction, which can affect memory encoding and free recall. A broad range of therapeutic approaches have been applied to older adults experiencing LLD along with cognitive symptoms, MCI, or dementia. Most studies focus on treatments to address LLD or MCI, with relatively fewer examining treatments specifically at this intersection. Nonpharmacological strategies, including aerobic exercise, cognitive remediation, and neuromodulation, are highly recommended to improve both depression and cognition. Antidepressants may have benefits for elements of cognition among people with LLD, but they have less evidence for their efficacy for people with cognitive deficits and dementia. This review provides an updated conceptual and practical framework for clinicians evaluating and treating LLD.

Indexed as

Alzheimer’s diseaseDementiaDepressive DisordersGeriatric depressionLate life depressionMild cognitive impairment

Identifiers

PMID40235602
PMCPMC11995896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.